

# Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

## pKK-BiFC-Venus

RRID:Addgene\_105804

Type: Plasmid

---

### Proper Citation

RRID:Addgene\_105804

---

### Plasmid Information

**URL:** <http://www.addgene.org/105804>

**Proper Citation:** RRID:Addgene\_105804

**Bacterial Resistance:** Ampicillin

**Defining Citation:** [PMID:29590189](#)

**Vector Backbone Description:** Backbone Marker:Sammarco & Grabczyk (PMID: 16212928); Vector Backbone:BI-16 (constructed based on pcDNA5/FRT/TO from Invitrogen); Vector Types:Mammalian Expression, Flp-In competent; Bacterial Resistance:Ampicillin

**Comments:** Addgene has found the VN173 mutation (I152L) is not present in this plasmid. This vector is a member of the pKK vector family. It enables concomitant expression of two genes, which transcription is driven by a tetracycline responsive bidirectional CMV promoter. This vector is a derivate of the BI16 plasmid (PMID: 16212928) and is suitable for stable cell line generation using the Flp-In system (see Szczesny RJ et al. for detailed description and protocols; bioRxiv, doi: <https://doi.org/10.1101/160101>). pKK-BiFC-Venus vector encodes fragments of Venus (VN173, VC155) that become fluorescent when they reassemble into full fluorescent protein. Thus, it is useful for protein-protein interactions studies involving bimolecular fluorescence complementation approach (BiFC) (PMID: 16454041, 18846096). Here, an improved version of VN173 fragment is used (I152L) to inhibit self-assembly (PMID:21091444). Venus fragments coding sequences were cloned from Addgene ID: 22010 and 22011 and VN173 was subjected to site-directed mutagenesis to introduce mutation I152L.

**Plasmid Name:** pKK-BiFC-Venus

**Record Creation Time:** 20220422T221513+0000

**Record Last Update:** 20260912T091420+0000

---

## Ratings and Alerts

No rating or validation information has been found for pKK-BiFC-Venus.

No alerts have been found for pKK-BiFC-Venus.

---

## Data and Source Information

**Source:** [Addgene](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Jahid S, et al. (2022) Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. Cell reports, 39(1), 110641.

Hao Z, et al. (2021) ??-Glutamyl carboxylase mutations differentially affect the biological function of vitamin K-dependent proteins. Blood, 137(4), 533.